Genmab — Maj 2022
-
Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting https://www.proinvestor.com/investornyt/830162/genmab-announces-multiple-abstracts-to-be-presented-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting
-
Epco+R-CHOP i 1. linje dlbcl ser stærk ud. https://meetings.asco.org/abstracts-presentations/210249
-
Kan du ikke forklare mig, som uvidende pharma-mand, hvornår "knockout" er leveret i din optik, så har jeg lidt at måle med. Pft.
-
Epco er sc, glofi er iv. Så der er 1 punkt mere i epcos favør!
-
Sc glofi er på vej https://www.isrctn.com/ISRCTN17975931
-
Okay tak Bulder. Men epco er i det mindste først ude med SC…
-
Fine bemærkninger og Jeg kan ikke finde håret i suppen endnu. Kan også godt leve med, at Roche ikke får en knockout, så længe Epco viser sin overlegenhed
-
-
Winkel på CC: And I can assure you that a lot of data you haven't seen yet, this is a very heavily pretreated population, and we have not told you anything yet on complete responses, duration, etc., of dose responses and other color in the data set. So we believe the data set is very encouraging…
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind